One ingredient, two regulatory regimes — and counting

Before any precision-bred ingredient enters a UK product, it needs FSA authorisation — the Precision Breeding Act created a new category that sits outside the old GMO regime but still requires pre-market sign-off. The FSA is still building the authorisation framework; they published their approach in late 2024 but no applications have been determined yet. Your supplier would need to apply and receive a 'precision bred organism' marketing authorisation — a process that's expected to take 12–18 months from application. The good news is that once authorised, it doesn't require the GMO label. The bad news is there's no fast track, and the queue hasn't formed yet so timelines are genuinely uncertain.

That's where it gets complicated. The EU's NGT Regulation distinguishes between NGT1 (equivalent to conventional breeding, lighter-touch process) and NGT2 (more substantial modifications, full GMO-equivalent authorisation). The UK's precision breeding category doesn't map cleanly onto either — some UK-authorised varieties might qualify as NGT1 under EU rules, others might fall into NGT2. Until the EU Regulation is fully in force and the Commission publishes detailed criteria for categorisation, your supplier's ingredient may need separate EFSA assessment for EU sale. There's also a labelling divergence issue: NGT2 products require mandatory labelling in the EU that wouldn't be required in the UK for the equivalent product. So even if the same ingredient is legally usable in both markets eventually, your consumer-facing packaging may need to differ.

The Regulation entered into force in 2024, but the operative dates are staggered. NGT1 rules — the lighter category — apply from 2025 onwards for new varieties that meet the criteria. NGT2 authorisations use a transitional pathway through the existing GMO framework while the new system is stood up. The complication is that the catalogue of NGT1-eligible varieties has to be established first, and that's an EFSA workload question. Your regulatory team's different dates are probably all correct — they're referring to different parts of the Regulation. I'd run a deep dive specifically on the NGT1 categorisation criteria and the EFSA opinion pipeline; that's where the practical timeline visibility is.